Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Lineage Cell Therapeutics, with a price target of $2.00, indicating a potential upside of 106.19% from the stock's previous close.
• HC Wainwright also maintains a "buy" rating" but with a higher price target of $9.00, and five research analysts collectively rate the stock as a "buy" with a consensus target price of $4.20.
• Lineage Cell Therapeutics has recently seen increased investment, with 62.47% of its stock currently owned by institutional investors and hedge funds, showcasing growing confidence in the company's potential.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reaffirmed by D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $2.00 price target on the stock. D. Boral Capital's price objective would indicate a potential upside of 106.19% from the stock's previous close.

Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $0.97 on Tuesday. The company's 50 day simple moving average is $0.91 and its 200 day simple moving average is $0.65. Lineage Cell Therapeutics has a 12 month low of $0.37 and a 12 month high of $1.21. The firm has a market capitalization of $221.51 million, a PE ratio of -12.13 and a beta of 1.66.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Integrity Alliance LLC. increased its stake in Lineage Cell Therapeutics by 75.0% in the second quarter. Integrity Alliance LLC. now owns 35,000 shares of the company's stock valued at $32,000 after acquiring an additional 15,000 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Lineage Cell Therapeutics during the second quarter worth about $368,000. Ground Swell Capital LLC acquired a new stake in Lineage Cell Therapeutics during the second quarter valued at approximately $95,000. Cannon Global Investment Management LLC bought a new stake in shares of Lineage Cell Therapeutics in the 2nd quarter valued at approximately $30,000. Finally, Defender Capital LLC. raised its holdings in shares of Lineage Cell Therapeutics by 7.5% in the 2nd quarter. Defender Capital LLC. now owns 6,785,177 shares of the company's stock worth $6,157,000 after buying an additional 474,304 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.